KNSA vs NAGE: fair value comparison
Kiniksa Pharmaceuticals International, plc and Niagen Bioscience, Inc. · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, KNSA currently sits closer to the top of our discount ranking. NAGE carries the stronger quality grade.
| KNSA | NAGE | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $73.41 | $3.53 |
| 12-month range | $34.28–$73.41 | $3.33–$9.88 |
| Sector rank | #58 of 113 Healthcare | #62 of 113 Healthcare |
| Quality grade | D | C |
| Leverage | Low | Low |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: KNSA fair value analysis · NAGE fair value analysis